PharmTech News

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Articles

The company said this new commitment to its facility in Germany goes hand in hand with its recently announced ReciPredict, an initiative intended to streamline the product development cycle.

Recipharm Investment Will Enhance Oral Solid Development, GMP Pilot-Scale Suites

Novo Nordisk will use Korro Bio’s OPERA platform to develop RNA editing candidates for two targets to treat cardiometabolic diseases.

Korro Bio and Novo Nordisk Collaborate on Cardiometabolic Treatments

The approach makes use of clinical mass spectrometers that are already available in hospitals around the world.

University of Oxford Chemists Develop Method for Vaccine Authenticity Screening

Feliza Mirasol is the science editor for 

Phase III trial results showed that Imfinzi (durvalumab in combination with chemotherapy reduced the risk of recurrence, progression, or death by 32% in patients with resectable non-small cell lung cancer before and after surgery.

AstraZeneca’s Imfinzi Gets Expanded Indication in Lung Cancer on FDA Approval

The completed acquisition of Morphic expands Lilly's immunology pipeline with Morphic's oral integrin therapies for treating inflammatory bowel disease.

Completion of $3.2 Billion Morphic Acquisition Expands Lilly’s IBD Portfolio

PiaSky (crovalimab) has previously been approved in countries such as the United States and Japan for monthly, subcutaneous use that may be self-administered with adequate training.

Roche Treatment for Paroxysmal Nocturnal Hemoglobinuria Approved in EU

Opaganib was given orphan drug designation for the treatment of neuroblastoma in children, which is rare, but the most common infancy malignancy.

FDA Grants Orphan Drug Designation to RedHill’s Treatment for Neuroblastoma

In a 24-week study of patients with PAH, six-minute walking distance improved by an average of 40.8 meters, and risk of death or clinical worsening was reduced by 82%.

European Commission Approves Merck Treatment Combined with Other Therapies for Pulmonary Arterial Hypertension

The collaboration builds on Novartis’ acquisition of Chinook Therapeutics just over a year ago.

Novartis, Versant Create Borealis Biosciences to Develop Kidney Disease Treatments

Merck, known as MSD outside of the United States and Canada, will gain CN201, a next-generation bispecific antibody, from Curon Biopharmaceutical in a  deal potentially worth up to $1.3 billion. 

Bio/Pharma News